FDA/CDC
FDA/CDC
Do not withhold opioid addiction drugs from patients taking benzodiazepines
The FDA says the benefits of combining MAT drugs with CNS depressants outweigh the risks.
FDA/CDC
FDA gives nod to first mobile app for substance use disorders
The reSET application is designed as an adjunct to outpatient therapy for patients with SUD aged 18 years and older.
FDA/CDC
FDA advisory committee rejects opioids in children’s cough syrup
Adolescents are the most at-risk population for opioid misuse.
FDA/CDC
Austedo approved for treatment of tardive dyskinesia
The drug was also approved in April 2017 to treat chorea associated with Huntington’s disease.
FDA/CDC
Extended-release amantadine approved for treatment of dyskinesia in Parkinson’s
This is the first FDA approval for a drug to treat levodopa therapy-related dyskinesia in patients with Parkinson’s disease.
FDA/CDC
Abilify Maintena OK’d by FDA for adults with bipolar I disorder
Approval of the long-acting injectable form of aripiprazole is based on a 52-week withdrawal trial in adults.
FDA/CDC
Pain frequency varies by employment status
Previously employed adults are the most likely to experience daily pain.
News from the FDA/CDC
Opioid prescribing drops nationally, remains high in some counties
The CDC calls for “more consistency among health care providers” when it comes to prescribing opioids.
FDA/CDC
Endo removes Opana ER from market
The move is in compliance with an FDA request citing a spike in abuse of the opioid agonist.
FDA/CDC
Cotempla XR-ODT approved for children, adolescents with ADHD
Methylphenidate for ADHD now comes in a more convenient disintigrating tablet.
FDA/CDC
Mydayis approved for teens, adults with ADHD
Treatment can lead to improved symptoms of ADHD that can last up to 16 hours, phase III studies show.